Bronchiectasis Phenotype Identification Model for Adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, observational study at Assiut University that develops a phenotype-translation model (BPIM) by first identifying trajectory-based bronchiectasis phenotypes with latent class trajectory analysis and then translating those phenotypes into a supervised baseline classifier. It does not involve any treatment or intervention. The approach links to the BAS E framework for severity and exacerbation but remains a separate analytical track. Participants will undergo routine clinical, imaging, functional, and inflammatory assessments with planned longitudinal follow-up. The aim is to improve phenotype identification at baseline to support future risk stratification and personalized care.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult patients aged 18 years or older.
* Diagnosis of non-cystic fibrosis bronchiectasis (NCFB) based on clinical assessment and high-resolution computed tomography (HRCT).
* Patients attending outpatient clinics, inpatient wards, or respiratory follow-up services at Assiut University Hospitals during the study enrollment period.
* Patients suitable for baseline disease-signature assessment within the Bronchiectasis Phenotype Identification Model (BPIM) framework.
* Ability to undergo routine clinical, functional, radiological, oxygenation, and inflammatory assessment according to the study protocol.
* Ability to complete planned longitudinal follow-up required for latent class trajectory analysis (LCTA) and Bronchiectasis Phenotype Identification Model (BPIM) validation.
* Written informed consent obtained from the patient or legal representative.

Exclusion Criteria:

* Cystic fibrosis-related bronchiectasis.
* Traction bronchiectasis due to advanced fibrotic interstitial lung disease as the dominant respiratory diagnosis.
* Active pulmonary tuberculosis at enrollment.
* Active nontuberculous mycobacterial pulmonary disease requiring specific treatment at enrollment.
* Active malignancy or terminal non-respiratory illness expected to prevent planned follow-up.
* Acute life-threatening illness preventing safe enrollment or reliable baseline assessment.
* Recent major thoracic surgery or acute thoracic trauma interfering with baseline respiratory assessment.
* Inability to complete required baseline disease-signature assessment according to the Bronchiectasis Phenotype Identification Model (BPIM) protocol.
* Inability or unwillingness to complete planned longitudinal follow-up.
* Refusal to participate.

Where it's running

• Assiut university-Faculty of Medicine
  Asyut, Assiut Egypt, Egypt Recruiting

Study contacts

• Principal investigator: Ahmad M Shaddad, MD — Assiut University
• Study coordinator: Ahmad M Shaddad, MD
• Email: shaddad_ahmad@aun.edu.eg
• Phone: +201111171930

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Azithromycin added to usual care to see if it lowers bronchiectasis flare-ups

  This trial tests whether taking azithromycin daily for a year reduces bronchiectasis-related flare-ups in adults with non-cystic fibrosis bronchiectasis.

  Recruiting Phase 4 Assiut University · Asyut · NCT07608328

• BASE: Aiming to test a simple, objective way to gauge bronchiectasis severity and predict flare-ups

  This study tests a new BASE framework to classify how severe non-cystic fibrosis bronchiectasis is right now and see if it can predict 12 months of worsening or flare-ups.

  Recruiting Assiut University · Asyut, Asyut Egypt · NCT07599839

• Using hypertonic saline to improve mucus clearance in bronchiectasis

  This study is testing if a special salt solution delivered through a nebulizer can help adults with bronchiectasis clear mucus from their lungs better.

  Recruiting Phase 4 University of North Carolina, Chapel Hill · Chapel Hill, North Carolina · NCT06242795

• Chronic Respiratory Disease Participant Engagement

  This study tests whether adults with long-term lung conditions can get comfortable with a clinical trials unit and research team before joining future trials.

  Recruiting Richmond Pharmacology Limited · London · NCT07924462

• Bronchoscopic Amikacin for Acute Exacerbations in Bronchiectasis

  This study tests whether delivering amikacin directly into the lungs during bronchoscopy helps adults with acute bronchiectasis flare-ups.

  Recruiting First Affiliated Hospital of Ningbo University · Ningbo, Zhejiang · NCT07813299

• Galvokimig vs placebo for non-CF bronchiectasis in adults

  This study tests whether Galvokimig can delay the first pulmonary flare compared with placebo in adults with non-CF bronchiectasis.

  Recruiting at 7 sites Phase 2 UCB Pharma · Newport Beach, California and 6 other locations · NCT07720375

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.